<unk>  was an early candidate of alcohol replacement drugs that came to market during a late 2010s movement to replace alcohol with less-toxic alternatives spearheaded by British psychopharmacologist David Nutt rippling to the rest of Europe. In an act of gonzo journalism, Michael Slezak writing for New Scientist, tried and reported on his experience with<unk> .<unk>  is currently being prepared for FDA registration by Clearmind Medicine Inc (CSE:CMND). The company claims wide Intellectual Property Holding.<unk>  (5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) belongs to the indane family of molecules. It was a recreational drug and binge drinking prevention drug. Its molecular structure was first mentioned implicitly in a markush structure schema appearing in a patent from 1998. It was later explicitly and pharmacologically described in a peer reviewed paper in 2017 by David Nutt et al., followed by another in February 2018 which detailed the pharmacokinetics, pharmacodynamics and metabolism of<unk> . One year later it was studied an reported on in another peer reviewed paper. In 2018, a company in the United States began offering an<unk> -based drink called "Pace". The aminoindane family of molecules was, perhaps, first chemically described in 1980.
MEAI
OHVIRA
SCoRS
E-med
DRACO
FCM 
SCAPER
TOFI